Tunde Peto1,2, Tjebo F C Heeren2,3, Traci E Clemons4, Ferenc B Sallo2, Irene Leung2, Emily Y Chew5, Alan C Bird2. 1. Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom. 2. NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom. 3. University Eye Hospital, Bonn, Germany. 4. The Emmes Corporation, Rockville, Maryland. 5. National Eye Institute, Bethesda, Maryland.
Abstract
PURPOSE: To evaluate progression of macular telangiectasia Type 2 lesions and their correlation with visual acuity. METHODS: An international multicenter prospective study with annual examinations including best-corrected visual acuity (BCVA), fundus photography, fluorescein angiography, and optical coherence tomography images graded centrally. Mixed models were used to estimate progression rates, and a generalized linear model to compute the relative risk of BCVA loss, loss of ellipsoid zone (EZ) reflectivity, development of pigment plaques, or neovascularization. RESULTS: One thousand and fourteen eyes of 507 participants were followed for 4.2 ± 1.6 years. Best-corrected visual acuity decreased 1.07 ± 0.05 letters (mean ± SE) per year. Of all eyes, 15% lost ≥15 letters after 5 years. Of the eyes without EZ loss, 76% developed a noncentral loss. Of the eyes with noncentral loss, 45% progressed to central EZ loss. The rate of BCVA loss in eyes with noncentral EZ loss at baseline was similar to eyes without EZ loss. The rate of BCVA loss was significantly higher in eyes with central EZ loss at baseline (-1.40 ± 0.14 letters, P < 0.001). CONCLUSION: Ellipsoid zone loss is frequently found in macular telangiectasia Type 2 and is an important structural component reflecting visual function. Its presence in the fovea significantly correlates with worse visual prognosis.
PURPOSE: To evaluate progression of macular telangiectasia Type 2 lesions and their correlation with visual acuity. METHODS: An international multicenter prospective study with annual examinations including best-corrected visual acuity (BCVA), fundus photography, fluorescein angiography, and optical coherence tomography images graded centrally. Mixed models were used to estimate progression rates, and a generalized linear model to compute the relative risk of BCVA loss, loss of ellipsoid zone (EZ) reflectivity, development of pigment plaques, or neovascularization. RESULTS: One thousand and fourteen eyes of 507 participants were followed for 4.2 ± 1.6 years. Best-corrected visual acuity decreased 1.07 ± 0.05 letters (mean ± SE) per year. Of all eyes, 15% lost ≥15 letters after 5 years. Of the eyes without EZ loss, 76% developed a noncentral loss. Of the eyes with noncentral loss, 45% progressed to central EZ loss. The rate of BCVA loss in eyes with noncentral EZ loss at baseline was similar to eyes without EZ loss. The rate of BCVA loss was significantly higher in eyes with central EZ loss at baseline (-1.40 ± 0.14 letters, P < 0.001). CONCLUSION: Ellipsoid zone loss is frequently found in macular telangiectasia Type 2 and is an important structural component reflecting visual function. Its presence in the fovea significantly correlates with worse visual prognosis.
Authors: Ferenc B Sallo; Irene Leung; Mina Chung; Ute E K Wolf-Schnurrbusch; Alfredo Dubra; David R Williams; Traci Clemons; Daniel Pauleikhoff; Alan C Bird; Tunde Peto Journal: Ophthalmology Date: 2011-08-12 Impact factor: 12.079
Authors: Michael B Powner; Mark C Gillies; Marina Tretiach; Andrew Scott; Robyn H Guymer; Gregory S Hageman; Marcus Fruttiger Journal: Ophthalmology Date: 2010-08-03 Impact factor: 12.079
Authors: Tjebo F C Heeren; Traci Clemons; Hendrik P N Scholl; Alan C Bird; Frank G Holz; Peter Charbel Issa Journal: Invest Ophthalmol Vis Sci Date: 2015-06 Impact factor: 4.799
Authors: Peter Charbel Issa; Robert P Finger; Kathrin Kruse; Sönke Baumüller; Hendrik P N Scholl; Frank G Holz Journal: Am J Ophthalmol Date: 2011-02-19 Impact factor: 5.258
Authors: Wai T Wong; Farzin Forooghian; Zigurts Majumdar; Robert F Bonner; Denise Cunningham; Emily Y Chew Journal: Am J Ophthalmol Date: 2009-07-02 Impact factor: 5.258
Authors: Peter Charbel Issa; Tos T J M Berendschot; Giovanni Staurenghi; Frank G Holz; Hendrik P N Scholl Journal: Invest Ophthalmol Vis Sci Date: 2008-03 Impact factor: 4.799
Authors: Peter Charbel Issa; Eric Troeger; Robert Finger; Frank G Holz; Robert Wilke; Hendrik P N Scholl Journal: PLoS One Date: 2010-09-22 Impact factor: 3.240
Authors: Daniel Pauleikhoff; Roberto Bonelli; Adam M Dubis; Frederic Gunnemann; Kai Rothaus; Peter Charbel Issa; Tjebo Fc Heeren; Tunde Peto; Traci E Clemons; Emily Y Chew; Alan C Bird; Ferenc B Sallo Journal: Acta Ophthalmol Date: 2019-04-09 Impact factor: 3.761
Authors: Marin L Gantner; Kevin Eade; Martina Wallace; Michal K Handzlik; Regis Fallon; Jennifer Trombley; Roberto Bonelli; Sarah Giles; Sarah Harkins-Perry; Tjebo F C Heeren; Lydia Sauer; Yoichiro Ideguchi; Michelle Baldini; Lea Scheppke; Michael I Dorrell; Maki Kitano; Barbara J Hart; Carolyn Cai; Takayuki Nagasaki; Mehmet G Badur; Mali Okada; Sasha M Woods; Catherine Egan; Mark Gillies; Robyn Guymer; Florian Eichler; Melanie Bahlo; Marcus Fruttiger; Rando Allikmets; Paul S Bernstein; Christian M Metallo; Martin Friedlander Journal: N Engl J Med Date: 2019-09-11 Impact factor: 91.245
Authors: Tyler A Berger; Matthew W Manry; Lucas B Lindsell; James M Osher; Daniel M Miller; Robert E Foster; Christopher D Riemann; Michael R Petersen; Robert A Sisk Journal: Clin Ophthalmol Date: 2021-03-15